Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 5/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.33 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.33 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.33 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.33 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.33 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 4/20 | 0.33 |
| ▸ | KDR | P35968 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | RET | P07949 | 2/20 | 0.33 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.33 |
| ▸ | FLT3 | P36888 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10141196 | 0.83 | — | — | |
| SCHEMBL19596 | 0.83 | — | — | |
| SCHEMBL10141206 | 0.83 | — | — | |
| Hydrochloric Acid SCHEMBL28194910 | 0.81 | — | — | |
| Bromide SCHEMBL17747828 | 0.81 | — | — | |
| SCHEMBL27449483 | 0.81 | — | — | |
| Ethyne SCHEMBL7797558 | 0.79 | — | — | |
| Pyridine SCHEMBL28087033 | 0.78 | MAPT (0.43) | MAPTALDH1A1RAB9ALMNAGRIN2D | |
| SCHEMBL6938254 | 0.78 | TLK2 (0.38) | KMT2AMAPTALDH1A1RAB9ALMNA | |
| Methyl Alcohol SCHEMBL11864407 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1435962-A4 | TREATMENT OF TYPE I DIABETES | CELL PATHWAYS INC (US) | 2009-04-15 | — | — | EP | disclosed |
| EP-1435961-A4 | TREATMENT FOR LUPUS ERYTHEMATOSUS | CELL PATHWAYS INC (US) | 2005-04-20 | — | — | EP | disclosed |
| EP-1435940-A4 | TREATMENT OF SCLERODERMA | CELL PATHWAYS INC (US) | 2005-04-20 | — | — | EP | disclosed |
| EP-1435962-A2 | TREATMENT OF TYPE I DIABETES | Cell Pathways, Inc. (US) | 2004-07-14 | — | — | EP | disclosed |
| EP-1435782-A1 | TREATMENT FOR CYSTIC FIBROSIS | Cell Pathways, Inc. (US) | 2004-07-14 | — | — | EP | disclosed |
| EP-1435961-A2 | TREATMENT FOR LUPUS ERYTHEMATOSUS | Cell Pathways, Inc. (US) | 2004-07-14 | — | — | EP | disclosed |
| EP-1435940-A1 | TREATMENT OF SCLERODERMA | Cell Pathways, Inc. (US) | 2004-07-14 | — | — | EP | disclosed |
| WO-2003017925-A2 | TREATMENT OF TYPE I DIABETES | CELL PATHWAYS, INC. (US) | 2003-03-06 | — | — | WO | disclosed |
| WO-2003017765-A1 | TREATMENT FOR CYSTIC FIBROSIS | CELL PATHWAYS, INC. (US) | 2003-03-06 | — | — | WO | disclosed |
| WO-2003017926-A2 | TREATMENT FOR LUPUS ERYTHEMATOSUS | CELL PATHWAYS, INC. (US) | 2003-03-06 | — | — | WO | disclosed |
| WO-2003017999-A1 | TREATMENT OF SCLERODERMA | CELL PATHWAYS, INC. (US) | 2003-03-06 | — | — | WO | disclosed |
| WO-2002067936-A1 | METHODS FOR TREATMENT OF INFLAMMATORY BOWEL DISEASE | CELL PATHWAYS, INC. (US) | 2002-09-06 | — | — | WO | disclosed |
| EP-1044187-A1 | N-BENZYL-3-INDENYLACETAMIDES DERIVATIVES FOR TREATING NEOPLASIA | OSI Pharmaceuticals, Inc. (US) | 2000-10-18 | — | — | EP | disclosed |
| WO-1999031065-A1 | N-BENZYL-3-INDENYLACETAMIDES DERIVATIVES FOR TREATING NEOPLASIA | CELL PATHWAYS, INC. (US) | 1999-06-24 | — | — | WO | disclosed |